According to filings with the U.S. Securities and Exchange Commission, Novocuff is raising up to $26,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Amelia Degenkolb played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Novocuff
Novocuff, Inc. is a medical device company dedicated to improving pregnancy outcomes and reducing the risk of preterm birth. Preterm birth is the leading cause of death for infants under the age of one. According to the World Health Organization (WHO), preterm birth complications were responsible for approximately 1 million deaths in 2020. Novocuff has developed a groundbreaking medical device to address the complex problems associated with the preterm birth conditions of PPROM and short cervix. The Novocuff Cervical Control System (CCS) has been designed with the goal of stabilizing and closing the cervix to retain amniotic fluid and sustain cervical length, with the aim of extending pregnancy. 

To learn more about Novocuff, visit http://www.novocuff.com/
Novocuff Linkedin Page: https://www.linkedin.com/company/novocuff-inc/

Contact:
Amelia Degenkolb, Chief Executive Officer
408-598-2872

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.